UPDATE: Wedbush Downgrades MAP Pharmaceuticals to Neutral, Reiterates $25 PT on Likely Acquisition

In a report published Friday, Wedbush downgraded its rating on MAP Pharmaceuticals (NASDAQ: MAPP ) from Outperform to Neutral, and reiterated its $25.00 price target. Wedbush noted, “Allergan previously announced its intent to acquire Map Pharmaceuticals for $25 per share and Allergan initiated a tender offer which expired on February